Lauri Peil

This paper develops a third-generation IL-2 therapeutic that targets inflamed tissues via oxidation-specific epitopes, showing improved therapeutic benefit in multiple inflammation models.

The paper creates a dataset of antibody-antigen complexes with mutations and evaluates affinity prediction methods, finding that current models poorly predict binding effects compared to empirical methods.

This paper uses adaptive laboratory evolution to replace tryptophan in E. coli with a synthetic analog, revealing that stress response inhibition, not translation rigidity, limits genetic code expansion.

The paper introduces iRAP, a method to identify RNA-binding sites across the proteome, finding 1331 sites in 324 yeast proteins, many outside known domains.